Decoding the Diagnosis: Subtypes and Lab Results
At a Glance
Rhizomelic chondrodysplasia punctata (RCDP) is diagnosed through genetic testing, X-rays showing bone stippling, and blood tests measuring plasmalogen levels. Type 1 is the most common subtype, making up over 90% of cases due to a PEX7 gene mutation.
Understanding the specific “flavor” of RCDP your child has is a critical step in moving from the shock of diagnosis to a clear plan of action. While all forms of RCDP involve a struggle to create plasmalogens (essential fats for the brain and bones), the genetic cause and the level of “residual” (leftover) plasmalogens determine the clinical path ahead [1][2].
The Genetic Subtype Matrix
There are five known genetic types of RCDP. They are defined by which part of the “manufacturing line” for plasmalogens is broken. Type 1 is by far the most common, accounting for more than 90% of all cases [1][3].
| Subtype | Gene Mutation | Frequency | Key Biological Role |
|---|---|---|---|
| Type 1 | PEX7 | >90% | Imports proteins into the peroxisome [1] |
| Type 2 | GNPAT | Rare | Early step in making plasmalogens [4] |
| Type 3 | AGPS | Rare | Early step in making plasmalogens [5] |
| Type 4 | FAR1 | Very Rare | Creates fatty alcohols for plasmalogens [6] |
| Type 5 | PEX5 | Very Rare | A specific “long” version of the protein fails [7] |
Classic vs. Non-Classic RCDP
The “severity” of RCDP is often described as either Classic or Non-Classic (sometimes called “mild”). This is primarily determined by how much plasmalogen the body can still produce [2].
- Classic RCDP: Plasmalogen levels in red blood cells are extremely low or nearly absent. This typically leads to the most severe skeletal shortening and significant developmental challenges [2].
- Non-Classic RCDP: The body has some “residual” enzyme activity, meaning it can still make a small amount of plasmalogen—sometimes up to 43% of normal levels [2]. These children may have milder bone shortening and may achieve more developmental milestones [8].
The Diagnostic Toolkit
A definitive diagnosis typically relies on a combination of physical signs, biochemical markers, and genetic confirmation. In modern clinical practice, a confirmed bi-allelic genetic mutation often solidifies the diagnosis even if full biochemical panels were delayed [3].
1. Imaging (The Skeletal Survey)
X-rays are often the first clue. Radiologists look for two specific hallmarks:
- Epiphyseal Stippling: Small, dot-like calcifications (spots) near the ends of long bones and in the joints like the hips and shoulders [9].
- Coronal Clefts: A vertical split or line visible in the vertebral bodies (the bones of the spine) when viewed from the side [1].
2. Biochemistry (The Blood Work)
Two main blood tests help confirm the diagnosis:
- Red Blood Cell (RBC) Plasmalogens: This is the most important test. Low levels are a hallmark of all RCDP types [2].
- Phytanic Acid: This is a fatty acid found in dairy and beef. Most RCDP patients have elevated levels because they cannot break it down, though some Type 1 patients may have normal levels [3][2].
- VLCFAs (Very Long Chain Fatty Acids): In RCDP, these are typically normal. This is a crucial “negative” result used to rule out look-alike conditions like Zellweger Spectrum Disorder [10].
Pathology Report Checklist
When you receive your child’s lab and pathology results, ensure you have the following information documented:
- [ ] Genetic Subtype: Confirmation of mutations in PEX7, GNPAT, AGPS, FAR1, or PEX5.
- [ ] Plasmalogen Levels: Quantified results from a red blood cell (erythrocyte) test.
- [ ] Phytanic Acid Level: Noted as elevated or normal.
- [ ] VLCFA Profile: Confirmed as normal to rule out other peroxisomal disorders.
- [ ] Skeletal Survey Report: Documentation of “stippling” and spine “clefts” [1][3].
Once the diagnosis is clear, the next step is Building Your Child’s Care Team.
Common questions in this guide
What are the different genetic types of RCDP?
What is the difference between classic and non-classic RCDP?
What do doctors look for on an X-ray to diagnose RCDP?
What blood tests are used to confirm an RCDP diagnosis?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Which of the five genetic types (Type 1-5) does our child have, and what specific genes were tested?
- 2.What was the exact plasmalogen level in the red blood cell test, and does this fall into the 'classic' or 'non-classic' range?
- 3.Can you walk us through the skeletal survey—specifically, were there coronal clefts in the spine or stippling in the joints?
- 4.Were the Very Long Chain Fatty Acids (VLCFAs) normal? How does this rule out other conditions like Zellweger Spectrum Disorder?
- 5.Since phytanic acid levels can be normal in some Type 1 cases, how did that factor into our child's diagnosis?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (10)
- 1
A new GNPAT variant of foetal rhizomelic chondrodysplasia punctata.
Cordisco A, Pelo E, Di Tommaso M, Biagiotti R
Molecular genetics & genomic medicine 2021; (9(8)):e1733 doi:10.1002/mgg3.1733.
PMID: 34110102 - 2
Clinical, biochemical, and molecular characterization of mild (nonclassic) rhizomelic chondrodysplasia punctata.
Fallatah W, Schouten M, Yergeau C, et al.
Journal of inherited metabolic disease 2021; (44(4)):1021-1038 doi:10.1002/jimd.12349.
PMID: 33337545 - 3
Type 1 rhizomelic chondrodysplasia punctata with a homozygous PEX7 mutation.
Muratoğlu Şahin N, Bilici ME, Kurnaz E, et al.
Journal of pediatric endocrinology & metabolism : JPEM 2017; (30(8)):889-892.
PMID: 28742517 - 4
Neonatal rhizomelic chondrodysplasia punctata type 2 caused by a novel homozygous variant in the GNPAT gene.
Sayed J, Gamal A, Theyab A, et al.
Clinical case reports 2023; (11(6)):e7504 doi:10.1002/ccr3.7504.
PMID: 37323250 - 5
The type-2 peroxisomal targeting signal.
Kunze M
Biochimica et biophysica acta. Molecular cell research 2020; (1867(2)):118609 doi:10.1016/j.bbamcr.2019.118609.
PMID: 31751594 - 6
Growth charts for individuals with rhizomelic chondrodysplasia punctata.
Duker AL, Niiler T, Eldridge G, et al.
American journal of medical genetics. Part A 2017; (173(1)):108-113 doi:10.1002/ajmg.a.37961.
PMID: 27616591 - 7
A novel type of rhizomelic chondrodysplasia punctata, RCDP5, is caused by loss of the PEX5 long isoform.
Barøy T, Koster J, Strømme P, et al.
Human molecular genetics 2015; (24(20)):5845-54 doi:10.1093/hmg/ddv305.
PMID: 26220973 - 8
Rhizomelic chondrodysplasia punctata morbidity and mortality, an update.
Duker AL, Niiler T, Kinderman D, et al.
American journal of medical genetics. Part A 2020; (182(3)):579-583 doi:10.1002/ajmg.a.61413.
PMID: 31769196 - 9
Expanding the genotypic and phenotypic landscapes of rhizomelic chondrodysplasia punctata type 3 (RCDP3) with two novel families, and a review of the literature.
İli EG, Gezdirici A, Di Pietro E, et al.
American journal of medical genetics. Part A 2022; (188(11)):3229-3235 doi:10.1002/ajmg.a.62959.
PMID: 35986576 - 10
Application of machine learning algorithms for the differential diagnosis of peroxisomal disorders.
Subhashini P, Jaya Krishna S, Usha Rani G, et al.
Journal of biochemistry 2019; (165(1)):67-73 doi:10.1093/jb/mvy085.
PMID: 30295825
This page is for informational purposes only and does not replace professional medical advice. Always consult your child's geneticist or healthcare team for help interpreting specific genetic and lab results.
Get notified when new evidence is published on Rhizomelic chondrodysplasia punctata.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.